This is a news story, published by CNBC, that relates primarily to Moderna news.
For more Moderna news, you can click here:
more Moderna newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Covid vaccine sales. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Covid market news, Moderna news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
quarterly lossCNBC
•Health
Health
87% Informative
Moderna beat on fourth-quarter revenue but lost more than expected for the period.
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its Covid vaccine.
Moderna reiterated its full-year 2025 product sales guidance of $1.5 billion to $2.5billion .
Cost of sales for the fourth quarter was $739 million , down 20% from the same period a year ago .
Research and development expenses dropped by 20% to $1.1 billion .
Moderna expects a decision from the FDA on the next-generation Covid shot in May , and a potential expanded approval for RSV in June .
VR Score
93
Informative language
95
Neutral language
87
Article tone
formal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links
